Technologies Enabling Dendritic Cell Targeting for Autoimmune/Inflammatory Disease Therapy

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across technologies that enable dendritic cell targeting for autoimmune/inflammatory disease therapy. Respiratory inflammation, myasthenia gravis, systemic lupus erytematosus, and other autoimmune disorders are profiled in the TOE. Recent patents related to dendritic cell targeting for autoimmune diseases have also been profiled.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered inclu

Table of Contents

Technologies Enabling Dendritic Cell Targeting for Autoimmune/Inflammatory Disease TherapyAdvances in Dendritic Cell Targeting Technologies for the Management of Autoimmune/Inflammatory DisordersRole of Psoriatic Inflammation in Regulating Airway InflammationEnhancing Immune Tolerance in Myasthenia GravisRole of Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus Repurposing BVDU for the Treatment of Autoimmune DisordersPatent Analysis and Industry InteractionsPatent ScenarioPatent ScenarioSummary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.